# EDGAR Filing Document

**Accession Number:** 0001095981
**File Stem:** 0001193125-26-051379
**Filing Date:** 2026-2
**Character Count:** 7613
**Document Hash:** 87753dd9543f6210a2024c398d7d0fcb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-051379.hdr.sgml**: 20260213

**ACCESSION NUMBER**: 0001193125-26-051379

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20260209

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20260213

**DATE AS OF CHANGE**: 20260213

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PLUS THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001095981
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 330827593
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34375
- **FILM NUMBER:** 26632813

**BUSINESS ADDRESS:**
- **STREET 1:** 4200 MARATHON BLVD.
- **STREET 2:** SUITE 200
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78756
- **BUSINESS PHONE:** 737.255.7194

**MAIL ADDRESS:**
- **STREET 1:** 4200 MARATHON BLVD.
- **STREET 2:** SUITE 200
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78756

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CYTORI THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20050712

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MACROPORE INC
- **DATE OF NAME CHANGE:** 20010320

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** February 9, 2026<br>

------

PLUS THERAPEUTICS, INC.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-34375 | 33-0827593 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 6420 LEVIT GREEN BOULEVARD<br>Suite 310 |  |  |
| Houston**,** Texas |  | 77021 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (737) 255-7194<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share | PSTV | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 9, 2026, Plus Therapeutics, Inc. (the "Company") filed a Registration Statement on Form S-1 (File No. 333-292637) with the Securities and Exchange Commission (as amended, the "Registration Statement"). Pursuant to Instruction 1 to Item 402(c)(2)(iii) and (iv) of Regulation S-K, the "Summary Compensation Table for 2025 and 2024" included in the Registration Statement noted that the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") had not yet determined the amount of discretionary cash bonuses payable to the Company's principal executive officer and up to two of the most highly compensated executive officers other than the principal executive officer (the "Named Executive Officers") for the fiscal year ended December 31, 2025 ("Fiscal Year 2025"), and that the amounts of such discretionary cash bonuses would be disclosed in a Current Report on Form 8-K under Item 5.02(f) once the amounts are determined.

On February 9, 2026, the Compensation Committee approved discretionary cash bonuses payable to the Named Executive Officers for Fiscal Year 2025. In accordance with Item 5.02(f) of Form 8-K, set forth below is an updated "Summary Compensation Table for 2025 and 2024", which includes the amount of discretionary cash bonuses payable to the Named Executive Officers for Fiscal Year 2025, as well as the total compensation figures for the Company's Named Executive Officers for Fiscal Year 2025.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **NEO** | **Year** | **Salary**<br>**($)** | **Option**<br>**Awards**<br>**($)**<sup>(1)</sup> | **Restricted<br>Stock<br>Awards<br>($)**<sup>(1)</sup> | **Non-Equity**<br>**Incentive Plan**<br>**Compensation**<br>**($)** | **All Other**<br>**Compensation**<br>**($)**<sup>(2)</sup> | **Total**<br>**($)** |
| Marc H. Hedrick, M.D.<br>*President and Chief Executive Officer* | 2025 | 585000 | 3531841 | 1100647 | 305663  | 43581 | 5566732 |
| Marc H. Hedrick, M.D.<br>*President and Chief Executive Officer* | 2024 | 556400 | 335348 | —  | 321321 | 47216 | 1260285 |
| Andrew Sims<br>*Chief Financial Officer* | 2025 | 390000 | 810388 | 264154 | 149175  | 17562 | 1631279 |
| Andrew Sims<br>*Chief Financial Officer* | 2024 | 372750 | 74758 | —  | 156555 | 17053 | 621116 |
| Norman LaFrance, M.D.<sup>(3)</sup><br>*Former Chief Medical Officer* | 2025 | —  | —  | —  | —  | —  | —  |
| Norman LaFrance, M.D.<sup>(3)</sup><br>*Former Chief Medical Officer* | 2024 | 258446 | —  | —  | —  | 27466 | 285912 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The amounts in this column reflect the aggregate grant date fair value of share-based awards granted to our NEOs during the years indicated. In accordance with SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions computed in accordance with ASC Topic 718.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)This column includes standard benefits, including a 401K match, and health and life insurance premiums.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)On June 11, 2024, Dr. LaFrance stepped down from his position as the Company's Chief Medical Officer.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | PLUS THERAPEUTICS, INC.  |
| Date: | February 13, 2026 | By:  | /s/ Marc H. Hedrick, M.D.  |
|  |  |  | Marc H. Hedrick, M.D.<br>President and Chief Executive Officer  |

---

------